New biologics for Crohn's: Real-World results from china
NCT ID NCT04923100
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study looked back at 50 adults with Crohn's disease who were treated with two newer biologic drugs, Ustekinumab and Vedolizumab. The goal was to see how well the drugs controlled the disease and what side effects occurred. Researchers also wanted to find out which patient factors predicted a good response, and how drug levels in the blood related to effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 501655, China
Conditions
Explore the condition pages connected to this study.